NEW2026 Annual Stockholders’ Meeting – December 2, 2026|Click Here for Meeting Details and Proxy MaterialsMeeting Details & Proxy Materials
NYSE American: IGC

Investor Relations

Committed to transparency and the advancement of next-generation therapies for neurodegenerative diseases through rigorous science and AI-driven innovation.

79_IGC-Pharma-Aligns-Fiscal-Year-with-Calendar-Year-to-Enhance-U.S.-Investor-Comparability
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability 
Read More →
78_IGC-Pharma-Raises-Capital-to-Advance-IGC-AD1-Phase-2-Trial-and-AI-Platform
IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial 
Read More →